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The pharmacological treatment of major depression is mainly based on 
drugs elevating serotonergic (5-HT) activity. Specifically, selective 5-HT 
reuptake inhibitors, including Fluoxetine (FLX), are the most commonly used 
for treatment of major depression. However, the understanding of the 
mechanism of action of FLX beyond its effect of elevating 5-HT is limited. The 
interaction between serotoninergic system and neuropeptides signalling could 
be a key aspect. We examined the ability of the neuropeptide Galanin(1-15) 
[GAL(1–15)] to modulate the behavioral effects of FLX in the forced swimming 
test (FST) and studied feasible molecular mechanisms. The data show that 
GAL(1-15) enhances the antidepressant-like effects induced by FLX in the FST, 
and we demonstrate the involvement of GALR1/GALR2 heteroreceptor complex 
in the GAL(1-15)-mediated effect using in vivo rat models for siRNA GALR1 or 
GALR2 knockdown. 
Importantly, 5-HT1A receptors (5HT1AR) also participate in the GAL(1-15)/FLX 
interactions since the 5HT1AR antagonist WAY100635 blocked the behavioral 
effects in the FST induced by the coadministration of GAL(1-15) and FLX. The 
mechanism underlying GAL(1-15)/FLX interactions affected the binding 
characteristics as well as the mRNA levels of 5-HT1AR specifically in the dorsal 
hippocampus while leaving unaffected mRNA levels and affinity and binding 
sites of this receptor in the dorsal raphe. The results open up the possibility to 
use GAL(1-15) as for a combination therapy with FLX as a novel strategy for 
treatment of depression. 
  





Major Depression is the most frequent mood disorder, with a lifetime prevalence 
that has been reported to range from 7% to 21% (Albert et al., 2011). It is 
associated with a substantial functional impairment, diminished quality of life, 
increased burden both for patients and caregivers, as well as with a higher risk 
of mortality. 
Although several neurotransmitter systems and brain areas have been 
implicated in this pathology, the pharmacological treatment of major 
depression is mainly based on drugs elevating serotonergic (5-HT) 
activity (Blier and de Montigny, 1994; Jans et al., 2007). Specifically, selective 
5-HT reuptake inhibitors (SRRIs) are the most commonly used for treatment 
of major depression. In particular, Fluoxetine (FLX) is usually chosen for the 
treatment of symptoms of depression (Artigas, 2013). However the 
understanding of the mechanism of action of FLX beyond its effect of elevating 
5-HT is limited. Recent studies have also implicated several neuropeptides in 
the pathophysiology of depression in rodents and in the possibility to use them 
as a combined treatment with antidepressant drugs. 
In this context, the neuropeptide Galanin (GAL) (Tatemoto et al., 1983) is of 
particular interest. GAL is widely distributed in neurons within the Central 
Nervous System (CNS) and three GAL receptor (GALR) subtypes, GALR1-3 
with a high affinity for GAL have been cloned (Branchek et al., 2000; Mitsukawa 
et al., 2008). GALR1 and GALR3 mainly activate inhibitory G proteins Gi/Go, 
while GALR2 mainly couples to Gq/G11 to mediate excitatory signaling 
(Branchek et al., 2000; Wang et al., 1997). 
GAL participates in mood regulation and depression in rodents (Bellido et al., 
2002; Juhasz et al., 2014; Wang et al., 2016; Weiss et al., 1998). Thus, the 
activation of GALR1 and GALR3 results in a depression like behavior while 
stimulation of GALR2 leads to anti-depressant-like effects (Bartfai et al., 2004; 
Kuteeva et al., 2008; Lu et al., 2005). Recently, it has been described that 
GAL and its receptor GALR3 are differentially methylated and expressed 
in brains of major depression subjects in a region- and sex-specific 
manner (Barde et al., 2016). 




 In this context, GAL modulates 5-HT1A receptor (5-HT1AR) function at 
autoreceptor and postsynaptic level in the brain. In the dorsal raphe (DR), 
intracerebroventricular (icv) GAL induced a time-dependent reduction in 
affinity and an increase in the 5-HT1AR autoreceptor density( Razani et al., 
2001). At the post-synaptic level, GAL reduced the affinity of the 5-HT1AR 
in the ventral limbic cortex (Fuxe et al., 1988; Hedlund and Fuxe, 1996). 
Moreover, in hypothermia, locomotor activity and passive avoidance, icv 
GAL blocked post-synaptic 5-HT1AR function (Kehr et al., 2002; Misane et 
al., 1998; Razani et al., 2001). The antagonistic GALR-5-HT1AR interactions 
described in the brain, especially in the limbic forebrain regions and in the 
dorsal raphe, has been suggested to be of high relevance for depression (Fuxe 
et al., 1988; Hedlund and Fuxe, 1996; Kehr et al., 2002; Misane et al., 1998; 
Razani et al., 2001). 
 
Not only GAL but also the N-terminal fragments like GAL(1-15) are active in the 
CNS (Diaz-Cabiale et al., 2007; Diaz-Cabiale et al., 2010; Diaz-Cabiale et al., 
2005; Hedlund and Fuxe, 1996). Recently we described that GAL(1-15) induces 
strong depression-related and anxiogenic-like effects in rats and these effects 
were significantly stronger than the ones induced by GAL (Millon et al., 2015). 
The GALR1-GALR2 heteroreceptor complexes in the dorsal hippocampus and 
DR, areas rich in GAL(1-15) binding sites (Hedlund et al., 1992) were involved 
in these effects (Millon et al., 2015) and demonstrated also in cellular models 
(Borroto-Escuela et al., 2014).  
GAL(1–15) is also able to enhance the antidepressant effects induced by the 5-
HT1AR agonist 8-OH-DPAT in the forced swimming test (FST) (Millon et al., 
2016), effect that was again significantly stronger than the ones induced by 
GAL. Importantly, the mechanism underlying this action involved interactions at 
the receptor level in the plasma membrane with changes also at the 
transcriptional level. Thus, GAL(1–15) affected the binding characteristics as 
well as the mRNA levels of 5-HT1AR in the dorsal hippocampus and DR (Millon 
et al., 2016). 
 




In view of these results the purpose of the current study was to assess the 
ability of GAL(1–15) to modulate the behavioral effects of FLX. We have 
analyzed the effect of GAL (1–15) on FLX-mediated responses in a behavioral 
test of depression. We tested the involvement of GALR2 in the GAL (1–15) 
effect with the selective GALR2 antagonist M871 and using an in vivo rat model 
for siRNA GALR2 knockdown. The role of the GALR1 in the behavioral actions 
of GAL(1–15) were analyzed using an in vivo rat model for siRNA GALR1 
knockdown. Moreover, to study wether the effects of GAL(1–15) on FLX action 
were mediated via 5-HT1AR, we have analyzed the effect of the 5-HT1AR 
antagonist WAY100635 in the GAL(1-15)-mediated effect in the FST. We have 
also determined the binding characteristics and mRNA levels of 5-HT1AR in the 
DR and dorsal hippocampus after GAL(1-15)-FLX administration.  
 
MATERIALS AND METHODS 
 
Animals 
Male Sprague-Dawley rats obtained from CRIFFA, Barcelona (200-250gr) were 
maintained under a 12h dark/light cycle in temperature- and humidity-controlled 
conditions (22±2ºC, 55–60%). The animals had free access to food pellets and 
tap water. Behavioural tests were performed during the light phase of the 
diurnal cycle. All Experimental procedures were approved by the Institutional 
Animal Ethics Committee of the University of Málaga, Spain. 
Detailed descriptions on animal controlled-conditions, surgical preparation, icv 
injections, forced swim test (FST) and behavioral scores are available in 
Supplemental Information. 
 
Forced Swimming Test 
Previously to the test, the animals were adapted to experimental room and 
handled. All tests were performed between 13:00h and 16:00h during the light 
cycle. Two swimming sessions were conducted: a 15 min pre-test followed 24 h 
later by a 5 min test. Animals were individually placed in a vertical glass cylinder 
of 20 cm diameter containing water (25 ºC) to a height of 30 cm. (Detke and 
Lucki 1996; Kuteeva et al. 2007). The total duration of immobility, climbing and 




swimming behavior were recorded during the second 5 min test. The 
administration of drugs was performed between sessions. 
 
siRNA GALR1 and GALR2 Knockdown Rats. 
Knockdown rats were generated as previously described (Millon et al., 2015). 
Using real time quantitative PCR, we have previously performed a time 
course of GALR2 mRNA in dorsal hippocampus (Millon et al., 2015) and 
we had also performed a time course of GALR2 protein expression using 
quantification of immunohistochemical staining for GALR2 in 
hippocampus (Millon et al., 2015). The time course curve indicated a 
maximal reduction of GALR2 receptor protein expression 8 days after the 
injection (Millon et al., 2015). 
 Briefly, during the stereotaxic surgery, once the cannula is fixed, animals 
received an intracerebroventricular (icv) injection of 5 μg (0.35 nmol) of Accell 
Smart pool siRNA for GALR2 or GALR1 (Dharmacon). Animals had a recovery 
period of 8 days prior to behavioural test, the time required to reduce the levels 
of GAL receptors as previously described (Millon et al., 2015).  
 
Behavioural Assessment 
Groups of rats were assessed in the FST. The doses, injection schedule and 
mode of administration of substances were chosen based on previous work 
(Estrada-Camarena et al., 2003; Estrada-Camarena et al., 2006; Jorgensen et 
al., 2001; Millon et al., 2016). 
In the first set of experiments, we performed a dose-response curve of FLX. 
Groups of rats received three injections subcutaneously (sc) of FLX at the 
doses of 10mg/Kg or 2.5mg/Kg, or vehicle 23, 5 and 1 hour before the tests and 
an icv injection of artificial cerebrospinal fluid (aCSF) 15 min before the test. 
This pattern of injection was shown to produce effects of FLX in the FST similar 
to those obtained after chronic treatment and to those leading to its clinical 
effects in humans (Detke et al., 1997). This mode of injection was used in all the 
experiments of this study. 
In the second set of experiments, in order to evaluate the interaction of FLX 
with GAL(1-15) in the FST, groups of rats received three injections of sc 




FLX(2.5mg/Kg) or FLX(10mg/Kg) and a single icv injection of a threshold dose 
of GAL(1-15)(1nmol) 15 minutes before the test. Also we compared the effects 
between the coadministration of FLX(10mg/Kg) and GAL(1-15)(1nmol) or 
GAL(1nmol) in the FST. 
In a third set of experiments we determined the involvement of GALR1 and 
GALR2 in the effect of GAL(1-15) on FLX-mediated action. Groups of rats 
received three injections of sc FLX(10mg/kg), a single icv injection of GAL(1-15) 
(1nmol) and the GALR2 antagonist M871 (3nmol) icv alone or in combination. 
Also, in siRNA GALR1 or GALR2 knockdown rats we coadministered 
FLX(10mg/Kg) and GAL(1-15)(1nmol) in order to analyze the involvement of 
GALR1 and GALR2 receptors in the GAL(1-15)-mediated effect.  
 
To further study if the effects of GAL(1-15) on FLX action were mediated via the 
5HT1AR, groups of rats received three injections of sc FLX(10mg/kg) and 15 
minutes before the test a single icv injection of GAL(1-15) (1nmol) and 
5HT1AR antagonist WAY100635(6nmol) icv alone or in combination. 
 
Autoradiography and in situ hybridization histochemistry 
The procedure to perform receptor autoradiography and in situ hybridization 
histochemistry was previously described (Millon et al., 2015; Saenz del Burgo et 
al., 2013). Rats (n=6 per group) received the three injections of sc FLX or 
Vehicle and a single icv injection of GAL(1-15) or aCSF, and were sacrified 30 
min later. Coronal sections were obtained at the dorsal hippocampus and DR 
level (see Supplemental Information for details). 
 
Quantitative autoradiography  
Saturation experiments were performed using [3H]-8-OH-DPAT. Briefly, the 
sections were preincubated for 30 minutes at room temperature in 50mM Tris-
HCl buffer (pH 7.6) containing 4mM CaCl2, 0.01% ascorbic acid and 10mM 
pargyline. The sections were then incubated for 60 minutes at room 
temperature with [3H]-8-OH-DPAT in the same solution as above. Film 
exposure time for sections was 6 weeks (see Supplemental Information for 
details). 





In situ hybridization histochemistry 
The oligonucleotides complementary to the mRNA coding for 5-HT1AR are 
found in Supplemental information. Oligonucleotide labeling, in situ 
hybridization histochemistry and specificity controls have been described 
elsewhere (Pompeiano et al., 1992; Tomiyama et al., 1997). 




Measurements were made in the Dentate Gyrus (DG) and the CA1 area of the 
hippocampus (0.15 mm2). The ventral part of the midline area of the DR was 
analyzed using a square as a sampling field (0.09mm2) (see Supplemental 
Information for details). 
 
Statistical Analysis: 
Data are presented as the mean±SEM and samples number (n) are indicated in 
figure legends. All data were analyzed using GraphPad PRISM 4.0 (GraphPad 
Software, La Jolla, CA). For comparing two experimental conditions, Student’s 
unpaired t-test was performed. Otherwise, one-way analysis of variance 
(ANOVA) followed by Newman-Keuls comparison post hoc-test was performed. 
Differences were considered significant at P<0.05 (*P<0.05, **P<0.01, 
***P<0.001). The data from the saturation experiments were analyzed by non-
linear regression analysis for the determination of the dissociation constant (Kd) 






Dose-response to Fluoxetine 
As previously described, three injections of FLX given sc at 10mg/Kg induced 
an antidepressant-like effect in the FST in rats (Table S1). The overall one way 




ANOVA revealed a significant effect between treatments in immobility time 
(F2,20=4.628, p<0.05) and swimming time (F2,20=7.044, p<0.01) while no 
significant difference was observed in climbing time (F2,20=2.569, p=0.102). 
FLX(10mg/Kg) reduced the immobility (post hoc, p<0.05) and increased 
swimming time (post hoc, p<0.01) compared to controls and FLX 2.5mg/Kg. 
The three injections of sc FLX 2.5mg/Kg was considered as threshold in this 
test since it did not produce antidepressant-like effects compared to controls 
(Table S1). 
 
GAL(1-15) but not GAL enhances antidepressant-like effects of FLX  in the FST 
 
The coadministration of the three sc injections of the threshold dose of 
FLX(2.5mg/Kg) and a single icv injection of GAL(1-15)(1nmol) (Figure S1) 
induced antidepressant-like effects with a significant decrease in the immobility 
(F3,27=3.973, p<0.05) compared with the rest of the groups (Figure S1; post hoc 
p<0.05). Moreover, an increase in the swimming time (F3,28=4.137, p <0.05) 
compared with GAL(1-15) and controls was also observed (Figure S1; post hoc, 
p<0.05). 
The strong enhancement by GAL(1-15) of the antidepressant-like effects 
mediated by FLX was validated using the effective dose of FLX 10mg/kg in the 
FST. The threshold dose of GAL(1-15) 1nmol enhanced the antidepressant-like 
effects mediated by the three sc injections of FLX(10mg/kg) since the overall 
one way ANOVA revealed a reduction in the immobility time (F3,28=10.96, 
p<0.001) and an increase in the swimming time (F3,28=16.46, p<0.001) without 
effects on climbing time (F3,27=0.7554, p=0.5289) (Fig. 1). Icv GAL(1-15) 
significantly decreased the immobility time induced by the three injections of the 
effective dose of FLX (10mg/kg) by 50% in the FST (Figure 1; post hoc p<0.05). 
Moreover, an increase of the swimming time by about 40% versus FLX 
(10mg/kg) group was also observed (p<0.01). 
The coadministration of three sc injections of FLX(10mg/Kg) and a single icv 
injection of GAL(1nmol) lacked  effects on the immobility and  swimming 
behaviours compared to FLX (10mg/kg) in the FST (Figure 1). 
 




GAL Receptor subtypes involved in the GAL(1-15)–Fluoxetine interaction 
 
We tested the involvement of the GALR2 in the GAL(1–15)-FLX(10mg/kg) 
interaction with the selective GALR2 antagonist M871 and using an in vivo rat 
model of siRNA GALR2 knockdown. 
 
1.Effects of the GALR2 antagonist M871 
The GALR2 antagonist M871 3nmol significantly blocked the GAL(1–15)-
induced reduction of the immobility time (F3,28=10.20, p<0.001;post hoc, 
p<0.05), and the GAL(1–15)-induced increase in the swimming time 
(F3,29=15.75, p<0.001;post hoc,p<0.01) found after coadministration of a single 
icv injection of GAL(1-15) and the three sc injections of FLX (10mg/kg) in the 
FST (Figure 2A). The GALR2 antagonist M871 injected alone in the dose of 
3nmol lacked effects on immobility time (14112 sec) and swimming time 
(68.710 sec) in the FST. 
 
2. Effects of siRNA GALR2 knockdown 
Then, we used knockdown GALR2 rats to establish the involvement of the 
GALR2 in the interaction between GAL(1-15)(1nmol) and FLX(10mg/kg) (Figure 
2B).  
The one-way ANOVA revealed a significant effects of the treatment used in the 
immobility (F2,17=5.932, p<0.05) and swimming behaviours (F2,17=5.932, 
p<0.01). The three sc injections of FLX(10mg/kg) produced antidepressant-like 
effects in the siRNA GALR2 knockdown animals with a decrease in the 
immobility time (Figure 2B; post hoc p<0.05) and an increase in the swimming 
time (Figure 2B; post hoc p<0.01) compared to a control group of siRNA 
GALR2 knockdown rats. Moreover, the coadministration of the three sc 
injections of FLX(10mg/kg) and a single icv injection of GAL(1-15) in siRNA 
GALR2 knockdown animals did not produce a further reduction of the immobility 
time and a further increase in the swimming time compared to FLX alone 
(Figure 2B). GAL(1-15)(1nmol) injected alone lacked effects in the FST in 
knockdown GALR2 animals compared to control group in terms of immobility 
(14.73 s), swimming (81.73 s) and climbing times (604 s). 





3. Effects of  siRNA GALR1 knockdown 
An siRNA GALR1 knockdown in rats was used to determine the involvement of 
the GALR1 in the effect induced by GAL(1-15) on FLX in the FST. In this model, 
previously used in our laboratory, it was possible to validate a reduction by 30% 
of the expression of GALR1 by immunochemical assay in the CA1 area of the 
dorsal hippocampus (Figure 3C; t14=2.317, p<0.05) and DG (Figure 3C; 
t14=2.359, p<0.05).  
In the FST on the siRNA GALR1 knockdown rats, the three sc injections of 
FLX(10mg/Kg) produced antidepressant-like effects with a decrease in the 
immobility time (Figure 3A; t16=2,778, p<0,05) and an increase in the swimming 
time (Figure 3A; t16=2,041, p<0.05) compared to the control group of GALR1 
knockdown rats. Moreover, in a different set of experiments, the 
coadministration of the three sc injections of FLX(10mg/Kg) and a single icv 
injection of GAL(1-15)(1nmol) in GALR1 knockdown animals did not produce a 
statistically significant difference compared to FLX(10mg/kg) group alone in the 
immobility time (Figure 3B; t15=0.121) nor in the swimming time (Figure 3B; 
t14=0.319). 
 
5HT1AR is involved in the GAL (1-15)–FLX interaction 
 
To determine the role of 5HT1AR in the behavioral interaction between GAL(1-
15) and FLX  the 5HT1AR antagonist WAY100635 was used (Figure 4).  
The results confirmed that the 5HT1AR participates in this interaction as the 
5HT1AR antagonist WAY100635 (6nmol) significantly blocked the reduction in 
immobility time (F3,30=4.243, p<0.05;post hoc, p<0.05), and the increase in 
swimming time (F3,29=16.83, p<0.001;post hoc,p<0.01) induced by the 
coadministration of icv GAL(1-15) and the three injections of sc FLX(10mg/kg) 
in the FST (Figure 4). 
The 5HT1AR antagonist WAY100635 (6nmol) injected alone significantly 
increased the immobility time (10112 sec) (t13=2,617, p<0,01) and lacked 
effect in swimming time (876 sec) (t13=0,2135, p=0.4172) in the FST. 
However, the coadministration of three sc injections of FLX and a single icv 




injection of WAY100635 (6nmol) did not produce any difference compared with 




GAL(1–15)+FLX modify the mRNA levels and the binding characteristics of 5-
HT1AR in the dorsal hippocampus. 
 
1. 5-HT1A mRNA levels 
The coadministration of the three sc injections of FLX(10mg/Kg) and a single icv 
injection of GAL(1-15)(1nmol) produced a significant increase in the 5HT1AR 
mRNA levels in CA1 (Figure 5; F3,18=8.803, p<0.001; post hoc, p<0.05) and DG 
(Figure 4; F3,17=5.033, p<0.05; post hoc, p<0.05) of the dorsal hippocampus 
compared to controls and single treatments. This effect was not observed in the 
DR (Table S2; F3,19=0.983; p=0.422). 
Representative autoradiograms illustrate the increase of 5HT1AR mRNA levels 
in both areas, CA1 and DG, after the coadministration of the three sc injections 
of FLX (10mg/Kg) and the single icv injection of GAL(1-15)(1nmol) (Figure 5B). 
 
2. 5-HT1A agonist radioligand binding. Saturation curves 
In the autoradiographic experiments, the coadministration of the three injections 
of sc FLX (10mg/Kg) and a single icv injection of GAL(1-15)(1nmol) produced a 
significant decrease in the Kd value (Figure 6; t9=2.916, p<0.01) and in the 
Bmax value (Figure 6; t9=2.277, p<0.05) of the agonist radioligand [3H]-8-OH-
DPAT in the DG of the dorsal Hippocampus compared to FLX(10mg/Kg) alone.  
Representative autoradiograms with a low radioligand concentration (1nM) 
illustrate the increase of labelling (decrease in Kd values) in the DG 30 minutes 
after the coadministration of the three injections of sc FLX (10mg/Kg) and the 
single icv injection of GAL1-15 (1nmol) (Figure 6B). 
 
These effects were not observed in the CA1 area of the Hippocampus neither in 
the Bmax (Table S3; t9=0,9420, p=0,1854) nor in the Kd values (Table S3; 
t9=0,01385, p=0,4946) neither in the DR in the Bmax (Table S3; t9=0,8648, 








In the current study we describe for the first time that GAL(1-15) enhances the 
antidepressant-like effects induced by FLX in the FST. These effects were 
specific since GAL lacks effect. Indications were also obtained for the 
involvement of a GALR1/GALR2 heteroreceptor complex in the GAL (1-15)-
mediated actions based on the use of the specific GALR2 antagonist M871 and 
icv injections of GALR1 siRNA or GALR2 siRNA producing a reduction of 
GALR1 or GALR2, respectively.  
Importantly, 5HT1AR participates in the GAL(1-15)/FLX interactions since the 
5HT1AR antagonist WAY100635 blocked the behavioral effects in the FST 
induced by the coadministration of GAL(1-15) and FLX. The mechanism 
underlying the GAL(1-15)/FLX interactions involved increases in the affinity of 
5HT1AR agonist binding in the DG with changes also at the transcriptional level 
in both CA1 and DG. GAL(1-15)/FLX interactions affected the binding 
characteristics as well as the mRNA levels of 5-HT1AR specifically in the dorsal 
hippocampus while leaving the 5-HT1A mRNA levels receptor agonist binding 
unaffected in  the dorsal raphe.  
 
The FST is used as a behavioral test to predict the efficacy of antidepressant 
treatments. The FST is an attractive behavioral screen for antidepressant drugs 
since it is quick to perform, reliable across laboratories, and sensitive to the 
effects of all of the major classes of antidepressant drugs. In this test the main 
indication of an antidepressant-like action of any given compound is a decrease 
in immobility behavior (Detke et al., 1995a; Detke et al., 1995b). The scoring of 
the active behaviors swimming and climbing give additional information about 
the mechanism of action that mediates the antidepressant-like effect. In fact, 
selective 5-HT reuptake inhibitors decrease immobility and increase swimming 
behavior (Detke et al., 1995a; Detke et al., 1995b).  
In the current study FLX 10 mg/kg injected -23, -5 and -1 h before the 5 min test 
significantly reduced the immobility and increased swimming time in the FST. 




These results obtained agree with previous studies and validates the behavioral 
model used (Estrada-Camarena et al., 2006). Moreover, FLX at 2.5mg/kg lacks 
effects, results which are again in agreement with those of other authors (Detke 
et al., 1997). 
In the current work we demonstrated that GAL(1-15) enhanced FLX induced 
antidepressant effects in the FST. A decrease in immobility behavior and an 
increase of swimming behavior were observed following cotreatment with 
threshold doses of GAL(1-15) and of FLX (2.5 mg/kg). When administered 
alone, neither GAL(1–15) 1 nmol nor 2.5 mg/kg of FLX affected the 
performance in the test, indicating that GAL(1-15) and FLX interact to provoke 
the enhanced antidepressant like responses. Since GAL(1-15) at an effective 
dose induced a pro-depressive effect (Millon et al., 2015), the antidepressant 
effect could only be due to the enhancement of FLX action. Moreover, the 
strong enhancement by GAL(1-15) of the antidepressant FLX action was 
validated using an effective dose of FLX. 
It was demonstrated that GAL(1-15) involves GALR1-GALR2 interactions to 
enhance the antidepressant effects of FLX in the FST. GALR2 is involved in the 
GAL(1-15) effects since the GALR2 antagonist M871 blocked the enhancement 
of the FLX antidepressant effects induced by GAL(1-15). We were also able to 
block the ability of GAL(1-15) to enhance the FLX induced behavioral effects 
through use of rats with in vivo siRNA induced GALR1 or GALR2 knockdown, 
validating the concept that GAL(1-15) actions depend on the existence of 
GALR1-GALR2 heteroreceptor complexes in the brain. 
Moreover in siRNA GALR1 and GALR2 knockdown rats, FLX alone reduced the 
immobility and increased swimming time in the FST, showing that the effect of 
FLX is not affected by the reduction of GALR1 or GALR2 expression.  
 
We have previously described that GAL(1-15) alone acts through GALR1-
GALR2 heteroreceptor complexes which preferentially bind GAL(1–15) 
(Borroto-Escuela et al., 2014; Fuxe et al., 2012; Millon et al., 2016; Millon et al., 
2015) and these heteroreceptor complexes were observed in the nerve cells of 
the dorsal hippocampus and DR (Millon et al., 2015). The results in the current 
paper validate that the effects of GAL(1-15) through GALR1-GALR2 




hetereceptor complexes could be a key mechanism in depression. Furthermore, 
the enhancing effects of GAL(1–15) on FLX mediated actions in the FST were 
specific, since no effects were induced by GAL, which validates and extends 
the view of a specific role of GAL(1–15) in brain communication.  
 
The fact that the enhancement of the antidepressant action of FLX by GAL(1-
15) was blocked by the 5-HT1AR antagonist WAY100635 indicates that the 5-
HT1AR has a significant participation in this interaction. Several authors have 
reported that WAY100635 when administered together with an effective dose of 
FLX, cancels the action of this SSRI (Estrada-Camarena et al., 2006; Serres et 
al., 2000). However, if the antagonist is administered in a different time point, 
like in the current study, the antidepressant-like activity of FLX in the FST is 
maintained (Estrada-Camarena et al., 2006; Serres et al., 2000). This 
observation of a time-schedule of injection in which WAY100635 could not 
prevent the antidepressant-like activity of FLX alone in the FST is of high 
interest. It supports the notion that GAL(1-15) through agonist activation of 
allosteric GALR1-GALR2-5-HT1A receptor-receptor interactions in putative 
trimeric heteroreceptor complexes may include effects on the recognition, 
pharmacology and signaling of the participating 5-HT1AR protomers. Such 
events can facilitate the understanding of the mechanism for the enhancement 
of the antidepressant  actions of FLX by GAL(1–15). 
We have previously described that GAL(1-15) alone acts through GALR1-
GALR2 isoreceptor complexes (Fuxe et al. 2012; Fuxe et al. 2008; Millon et 
al. 2015; Borroto-Escuela et al. 2014). These complexes could operate via 
allosteric GALR1-GALR2 interactions that inhibit the Gq/G11-mediated 
signaling of the GALR2 protomer and switches the isoreceptor complex 
towards Gi/o-mediated signaling (Borroto-Escuela et al. 2014; Millon et al. 
2015).  
The FLX induced increases in extracellular levels of 5-HT may also favor 
the formation of putative higher order GALR1-GALR2-5-HT1A 
heteroreceptor complexes. In such a complex altered allosteric receptor-
receptor interactions can develop with an ability of the GALR1-GALR2 




component to enhance the 5-HT1A protomer signalling. This possibility 
remains to be tested. 
Because not only 5-HT1AR, but also 5-HT4, 5-HT2A, 5-HT3 and 5-HT7 
receptors are involved in modulating the effects of antidepressant 
treatments, the participation of other 5-HT receptor subtypes in the 
interaction should also be analized. 
 
We have recently described that GAL(1–15) enhanced the antidepressant 
effects induced by the 5-HT1AR agonist 8-OH-DPAT in the FST (Millon et al., 
2016). Thus, a significant decrease in the immobility and an increase in climbing 
behavior appeared after the coadministration of GAL(1-15) and 8-OH-DPAT 
and an increase of the swimming behavior versus the 8-OH-DPAT alone group 
was also observed (Millon et al., 2016). These antidepressant effects were 
independent of the locomotor activity, as the total distances reached and 
speed were equivalent between all the group (Millon et al., 2016). In the 
current work FLX, as a selective serotonin reuptake inhibitor binds to the 
serotonin transporter (SERT), thereby blocking 5-HT uptake and enhancing 5-
HT volume transmission through decreasing the clearance of extracellular 5-HT 
levels (Fuxe et al., 2010). 
This increase in extracellular levels of 5-HT leads to an activation of a 
panorama of 5-HT receptor subtypes including 5-HT1A homo and 
heteroreceptor complexes. We do not know which are the major types of 5-HT 
homo and heteroreceptor complexes involved in the antidepressant effects of 
FLX but the putative 5-HT1AR-GALR1-GALR2 heteroreceptor complexes are 
likely one relevant target for the mediation of the enhancement by GAL(1-15) of 
the antidepressant actions of FLX. 
In previous work it was found that GAL(1-15) affected the binding 
characteristics as well as the mRNA levels of 5-HT1AR in the dorsal 
hippocampus and DR (Millon et al., 2016). In this work we observed a 
modification in the binding characteristics and also in the mRNA levels of 5-
HT1AR after coadministration of FLX and GAL(1-15). In fact, the 
coadministration of GAL(1-15) and FLX induced an increase in the mRNA levels 
of postjunctional 5-HT1AR in the dorsal hippocampus and a decrease in Kd and 




Bmax values, specifically in the DG of the hippocampus. These results indicate 
an important role of postjunctional hippocampal 5-HT1AR and their expression 
in the GAL(1-15)-FLX interaction. Thus, no effects were observed in the DR on 
the binding characteristics of soma-dendritic 5-HT1A autoreceptors nor on their 
expression. 
In previous work, we observed that 10 minutes after icv GAL(1-15) 
administration, no effect was observed in the 5HT-1A receptors in the DR 
(Millon et al., 2016). Our results suggest that in the sort term, the DR is not 
the key nucleus in the antidepressant effects induced by GAL(1-15). 
However we cannot exclude that a potential enhancement in the firing rate 
of the ascending 5-HT DR neurons was induced by GAL(1-15) by 
counteracting the 5-HT induced autoreceptor signaling in spite of lack of 
effects on 5-HT1A autoreceptor recognition. 
 
In conclusion, our results indicate that icv GAL (1-15) enhances the 
antidepressant effects induced by FLX in the FST. The target for GAL(1-15) 
may mainly be 5-HT1AR-GALR1-GALR2 heteroreceptor complexes and their 
allosteric receptor-receptor interactions located postjunctionally in the dorsal 
hippocampus (Fuxe et al., 2012; Fuxe et al., 2008; Millon et al., 2016; Millon et 
al., 2015). In contrast, GAL appears to mainly target GALR1-5-HT1A and 
GALR2-5-HT1A heteroreceptor complexes (Borroto-Escuela et al., 2010; Millon 
et al., 2016; Millon et al., 2015). The results open up the possibility to use 
intranasal GAL(1-15) as a combination therapy with FLX as a novel strategy for 
treatment of depression. 
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Figure 1. Behavioural effects of the coadministration of effective dose of FLX 
(10mg/Kg) and GAL(1-15) (1nmol) or Galanin (1nmol) in the FST. FLX was 
administered subcutaneously (sc) 23, 5 and 1 hour before the test. CSFa, 




GAL(1-15) and Galanin were injected intracerebroventricular (icv) 15 min before 
the test. Data represents mean ± SEM of immobility, climbing and swimming 
time in FST during the 5 min test period (n=7-8 rats per group). *p<0.05, 
**p<0.01 versus all the groups; #p<0.05 versus Control according to one way 
ANOVA followed by Newman-Keuls Multiple Comparison Test. 
 
Figure 2. Behavioural effects of the coadministration of effective dose of FLX 
(10mg/Kg) and threshold doses of GAL(1-15) (1nmol) in (A) Sprague-Dawley 
rats which also were treated with GALR2 antagonist M871 (3nmol) or (B) 
GALR2 knockdown rats (siRNA GALR2). FLX or vehicle was administered 
subcutaneously (sc) 23, 5 and 1 hour before the test. aCSF, GAL(1-15) and 
GAL(1-15)+M871 were injected intracerebroventricularly (icv) 15 min before the 
test. Data represents mean ± SEM of immobility, climbing and swimming times 
in FST during the 5 min test period (n=7-9 rats per group). #p<0.05, ##p<0.01 
versus FLX10mg(sc)+CSFa(icv) and FLX10mg(sc)+GAL(1-15) 1nmol+M871 
3nmol (icv); *p<0.05, **p<0.01 versus Control according to one way ANOVA 
followed by Newman-Keuls Multiple Comparison Test. 
 
Figure 3. Behavioural effects of effective dose of FLX 10mg/Kg (A) and 
coadministration of FLX 10mg/Kg and threshold doses of GAL(1-15)(1nmol) (B) 
in GALR1 knockdown rats (siGalR1). FLX and vehicle was administered sc 23, 
5 and 1 hour before the test. CSFa, GAL(1-15) were injected icv 15 min before 
the test. Data represents mean±SEM of immobility, climbing and swimming time 
in FST during the 5 min test period (n=7-9 rats per group) *p<0.05 according to 
Student’s unpaired t-test. (C) GALR1 protein expression eight days after a 
single i.c.v. injection of siRNA GALR1 or vehicle into the rat brain. Data are 
represents as mean±SEM of the percentages respect the control value (100%) 
of optic density (O.D) *p<0.05 according to Student’s unpaired t-test. (D) 
Representative photographs of GALR1 immunohistochemistry 
 
Figure 4. Behavioural effects of the coadministration of effective dose of FLX 
(10mg/Kg) and 5-HT1A antagonist WAY100635 (6nmol) and the 
coadministration of effective dose of FLX (10mg/Kg) with GAL(1-15) (1nmol) 




and WAY100635 (6nmol) in the FST. FLX was administered sc 23, 5 and 1 hour 
before the test. GAL(1-15), WAY100635 and GAL(1-15)+WAY100635 were 
injected icv 15 min before the test. Data represents mean ± SEM of immobility, 
climbing and swimming times in FST during the 5 min test period (n=5-10 rats 
per group). *p<0.05, **p<0.01 versus all groups according to one-way ANOVA 
followed by Newman-Keuls Multiple Comparison Test. 
 
Figure 5. (A) Effects of the coadministration of FLX (10mg/Kg) and GAL(1-15) 
(1nmol) on 5-HT1AR mRNA levels in dorsal hippocampus (CA1 and DG). FLX 
was administered sc 23, 5 and 1,25 hour before sacrifice and GAL(1-15) was 
injected icv 30 min before sacrifice. The values of optical density (O.D.), mean± 
SEM (n=6 per group), are expressed as percentages respect of the control 
values (100%). *p<0.05 versus all groups according to one way ANOVA 
followed by Newman-Keuls Multiple Comparison Test (B) Representative 
autoradiograms from dorsal hippocampus showing the levels of mRNA coding 
for 5-HT1AR determined by in situ hybridization and the analyzed areas. 
 
Figure 6. Effects on the binding characteristics of 5-HT1AR agonist [3H]-8-OH-
DPAT in the dental gyrus (DG) of the hippocampus (A) after the 
coadministration of FLX (10mg/Kg) and aCSF or GAL(1-15) (1nmol). FLX was 
administered sc 23, 5 and 1,25 hour before sacrifice and GAL(1-15) or CSFa 
was injected icv 30 min before. Saturation experiments were performed with ten 
concentrations of [3H]-8-OH-DPAT (0.26-10nM) in sections from the 
Hippocampus. Non-specific binding was defined as the binding in the presence 
of 10μM serotonin. The Kd and the Bmax values are shown as mean±SEM 
(n=6 per group). In FLX(10mg/kg) the Kd (nM) value was 1.2±0.1 and Bmax 
(fmol/mg prot) was 545±37. *p<0.05; **p<0.01 according to Student´s unpaired 
t-test. (B) Representative autoradiograms from Hippocampus sections of rat 
showing an increase of the afinity of the agonist for 5-HT1AR with a low 
concentration of the radioligand (1 nM). 
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